Stakeholders seek risk-based approach from FDA on regulating AI/ML for drug development
Regulatory NewsFerdous Al-Faruque
BiologicsCombination ProductsDiagnosticsMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyRegulatory NewsFerdous Al-FaruqueBiologicsCombination ProductsDiagnosticsMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy